Merrimack Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers.
Adequate balance sheet and overvalued.
Share Price & News
How has Merrimack Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MP6N's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: MP6N underperformed the German Biotechs industry which returned -5.4% over the past year.
Return vs Market: MP6N underperformed the German Market which returned -17.5% over the past year.
Price Volatility Vs. Market
How volatile is Merrimack Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Merrimack Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MP6N's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MP6N's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MP6N is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: MP6N is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MP6N's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MP6N is good value based on its PB Ratio (1.6x) compared to the DE Biotechs industry average (3.6x).
How is Merrimack Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Merrimack Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Merrimack Pharmaceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Merrimack Pharmaceuticals competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Merrimack Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MP6N is currently unprofitable.
Growing Profit Margin: MP6N is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MP6N is unprofitable, but has reduced losses over the past 5 years at a rate of 21.3% per year.
Accelerating Growth: Unable to compare MP6N's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MP6N is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).
Return on Equity
High ROE: MP6N has a negative Return on Equity (-122.85%), as it is currently unprofitable.
How is Merrimack Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: MP6N's short term assets ($18.7M) exceed its short term liabilities ($2.8M).
Long Term Liabilities: MP6N has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: MP6N is debt free.
Reducing Debt: MP6N currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Inventory Level: MP6N has a low level of unsold assets or inventory.
Debt Coverage by Assets: MP6N's debt is not covered by short term assets (assets are -11.6x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MP6N has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MP6N has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Merrimack Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MP6N's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate MP6N's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MP6N's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MP6N's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MP6N's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Gary Crocker (67yo)
Mr. Gary L. Crocker, MBA, has been President (Principal Executive Officer) and Treasurer (Principal Financial and Accounting Officer) of Merrimack Pharmaceuticals, Inc. since June 28, 2019. He is Chief Exe ...
CEO Compensation Analysis
Compensation vs Market: Gary's total compensation ($USD122.86K) is below average for companies of similar size in the German market ($USD432.27K).
Compensation vs Earnings: Gary's compensation has been consistent with company performance over the past year.
|Co-Founder and Scientific Advisor||no data||US$24.75k||no data|
|Senior Director of Communications||no data||no data||no data|
|Head of Human Resources||2.83yrs||no data||no data|
|Senior Vice President of Manufacturing||13.92yrs||US$690.77k||no data|
|Head of Research||3yrs||US$817.30k||no data|
|Secretary||no data||no data||no data|
Experienced Management: MP6N's management team is considered experienced (2.9 years average tenure).
|Member of Scientific Advisory Board||2.08yrs||US$98.89k||no data|
|Co-Founder & Director||5.17yrs||US$92.93k||0.17% $42.8k|
|Independent Director||5.17yrs||US$99.43k||0.0075% $1.9k|
|Member of Scientific Advisory Board||no data||no data||no data|
|Member of Scientific Advisory Board||2.17yrs||no data||no data|
|Chairman of Scientific Advisory Board||no data||no data||no data|
|Member of Scientific Advisory Board||2.08yrs||no data||no data|
|Director||0.50yr||no data||no data|
|Member of Scientific Advisory Board||2.08yrs||no data||no data|
Experienced Board: MP6N's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Merrimack Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Merrimack Pharmaceuticals, Inc.
- Ticker: MP6N
- Exchange: BST
- Founded: 1993
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$27.963m
- Listing Market Cap: US$25.220m
- Shares outstanding: 13.38m
- Website: https://www.merrimack.com
Number of Employees
- Merrimack Pharmaceuticals, Inc.
- One Broadway
- 14th Floor
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MACK||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Mar 2012|
|A1JHBG||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Mar 2012|
|MP6N||BST (Boerse-Stuttgart)||Yes||Common Stock||DE||EUR||Mar 2012|
Merrimack Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5. The company has a collaboration and license agreement with Ipsen S.A. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is based in Cambridge, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/28 00:24|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.